Fair-Value Report — Sipai Health Technology (0314.HK)

Rating caps / flags fired

• FALLING_KNIFE (price 54% below its 52-week high; 52-week change about −57%): blocks Moderate Buy / Buy. The H1 2026 interim result (a swing to IFRS profit) is already reported, but normalized profit is only RMB 6.9m, so it is not a clean earnings inflection.
• Base case not ≥ +25% vs live price: no Speculative Buy or better.
• PRICE_MOVED: not fired (live HK$1.395 vs insider HK$1.40, −0.4%). RUN_UP, EXTENDED, TOKEN_BUY, MICRO_ILLIQUID, NON_INSIDER_BUYER: not fired. Trade value HK$10.19m is about 1.0% of market cap.
• Step 1b: no going-concern, placing or lock-up issue found (see below); no cap from those. The next-print test does not apply (FY2026 results are not due within 60 days).

Insider signal

Verified snapshot

• Currency: Prices are in HKD; company financials are in RMB. I use about RMB 1 = HK$1.15, the rate implied by stockanalysis.com's HK$1.48 book value per share. Other sources suggest RMB 1 ≈ HK$1.18. I could not confirm the rate from a primary source, so HKD conversions of RMB figures are approximate (±3%).
• Source limits: I could not open AAStocks (the page returned only navigation), so the live price rests on the screener's market_context and stockanalysis.com, both dated 9 Oct 2026. I did not run an HKEX titleSearch listing; announcements were read via search and the PDFs.
• Latest financials: Interim results to 30 Jun 2026 (published 20 Aug 2026, reviewed by Ernst & Young), so the data is fresh and the recency guardrail does not apply.

Business

Sipai is a China healthcare services group with three segments: specialty pharmacy (dispensing high-cost drugs), physician research assistance, and commercial health-insurance services (corporate insurance plus the Hui Min Insurance product). It has 3,449 employees.

• Total gross profit fell 15.7% (RMB 176.1m to 148.5m). Margin rose only because the low-margin pharmacy line shrank. The profit pool did not grow.
• Operating profit moved from −RMB 60.4m to +RMB 0.2m. IFRS net profit of RMB 42.9m includes non-operating items (normalization removes share-based pay, restructuring and disposal gains); normalized net profit was RMB 6.9m. FY2025 normalized net loss was reported at RMB 47.6m (company results, via press summaries).
• Operating cash flow was −RMB 26.6m (H1 2025: −RMB 63.5m). Better, but the business still consumes cash.
• No interim dividend. Gearing (total liabilities / total assets) was 47.2%.

Valuation

Method: asset-based (P/B with quality haircuts) plus scenarios. The business is at best break-even on a normalized basis and the largest segment is shrinking by more than half. A DCF would rest on a recovery that is not yet reported, and price/sales does not apply to a 6.5%-margin pharmacy line. The valuation therefore rests on a book value made up mostly of cash and cash-like assets.

Book value quality (30 Jun 2026, RMB m)

• Cash and equivalents 158.4; time deposits 56.4; FVTPL products (incl. a US$22m JPMorgan wealth product) 305.0; pledged deposits 272.9. Together about 792.7.
• Of the pledged deposits, RMB 259.8m is a deposit tied to the pending acquisition of Hai Nan Shanze (100% of Shanze Technology, which holds about 98.3% of Jianyi Information Technology). Base consideration is RMB 354.5m plus RMB 5.5m for the remaining 1.68%, in total about RMB 360m, with a price-adjustment mechanism and RSU grants. As of the results date the deal had not completed. If it completes, about RMB 360m of cash becomes an operating asset whose earnings I could not verify.
• "Cash held on behalf of clients" (RMB 276.3m) is excluded from the figures above because it is matched by other payables (RMB 475.7m).
• Working-capital assets: trade and bills receivables 180.0; contract assets 247.4 (together RMB 427m, over 45% of equity). These are the main impairment risk in a bear case.
• Non-controlling interests are negative (−RMB 37.5m), which is why parent equity (932.4) exceeds total equity (895.0).

Scenarios (per share, HK$; book ≈ HK$1.47)

The bear case is deliberately not within 15% of the price. Book value is not treated as a floor: ROE is near zero, normalized earnings are barely positive, and most of the book is cash that is partly earmarked for an acquisition.

Reverse read

Market cap ≈ HK$1.01bn against cash and selected financial assets of about RMB 793m ≈ HK$0.91bn (about HK$1.25/share). The market therefore values the operating business at roughly HK$0.1bn, close to nil, against H1 gross profit of RMB 148m and normalized net profit of RMB 6.9m. That is not obviously expensive, but the discount is justified if cash is spent on a RMB 360m acquisition and operating cash flow stays negative. After the deal, cash would drop to roughly RMB 430m (about HK$0.68/share) and the rest of the market cap would depend on Jianyi and the insurance segment.

Peer table

The peers are much larger and profitable, so they are weak comparables, and I could not verify a third like-for-like peer. I do not apply their multiples. They are shown only to illustrate that profitable platforms trade above book while Sipai, with ROE near zero, trades at about book. A discount to profitable peers is consistent with its returns. Sipai's P/S is my calculation from stockanalysis revenue of HK$1.83bn.

Conclusion

The signal is real: the chairman and the other executive director each bought about HK$5m with their own money at HK$1.40, and the company has been repurchasing shares. But at HK$1.395 the stock trades at about book value, the book is mostly cash that is partly committed to an unproven acquisition, receivables and contract assets are large, and the biggest segment is shrinking by more than half. The base case gives no upside, and the bear case is about −35%. Rating: Hold. It would need a lower price (a clear discount to net cash after the acquisition) or reported evidence that normalized profit and operating cash flow are positive to justify a Buy.

Catalyst calendar

• Ongoing: Company share buyback (up to 72.99m shares under the 18 Jun 2026 mandate; 22.4m bought as of 15 Jul 2026).
• Undated: Completion (or failure) of the Hai Nan Shanze / Jianyi acquisition (RMB 360m). The date was not disclosed in the interim announcement.
• Estimated, not confirmed: late March 2027 — FY2026 annual results (based on this company's past pattern of March announcements). The next results are not within 60 days, so the next-print test does not apply.
• Estimated: August 2027 — H1 2027 interims.
• No placing, rights issue or convertible bond found within ±30 days of the 15 Jul 2026 event. No profit warning other than the positive alert preceding the H1 turnaround.

Key risks

• Acquisition risk: RMB 360m (about 40% of equity) for a target whose earnings I could not verify; price adjustment and RSU terms add uncertainty.
• Revenue decline: Specialty pharmacy revenue −55.8%; total revenue −39.6%; gross profit −15.7%.
• Earnings quality: IFRS profit RMB 42.9m vs normalized RMB 6.9m; operating cash flow still negative.
• Working-capital impairment: RMB 427m of receivables and contract assets.
• Capital allocation: Buybacks at about HK$2.00 average are already under water against the current price; further buybacks at HK$1.40 are cheaper but consume cash needed for the acquisition.
• Data limits: FX rate approximated; AAStocks not accessible; FY2025 audit report not re-read for going-concern wording (the H1 text reviewed by E&Y contains no going-concern or material-uncertainty language).

What would prove us wrong

• Upside (we are too cautious): The acquisition completes with disclosed target profit of RMB 40m+ a year, or FY2026 normalized net profit comes in clearly above RMB 30m with positive operating cash flow.
• Downside (we are too generous): A receivables or contract-asset impairment announcement, an acquisition price adjustment or write-down, or operating cash outflow widening beyond H1's RMB 27m.
• A further break below the insiders' HK$1.40 purchase price on volume with no company buyback response.

Sources

• Company voluntary announcement, 15 Jul 2026 (executive directors' purchase; share repurchases): hkexnews.hk/listedco/listconews/sehk/2026/0715/2026071501213.pdf
• Interim results announcement for the six months ended 30 Jun 2026, 20 Aug 2026: hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001213.pdf (English); Chinese version via pdf.dfcfw.com
• PR Newswire H1 2026 results release; 10jqka.com.cn H1 2026 summary
• stockanalysis.com statistics pages for 0314, 0241, 1833 (accessed 9 Oct 2026)
• Screener market_context for 0314 (live price, flags), 9 Oct 2026